BioNTech (NASDAQ:BNTX) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $113.00 target price on the stock. HC Wainwright also issued estimates for BioNTech’s Q3 2024 earnings at $0.86 EPS, Q4 2024 earnings at $0.63 EPS, FY2024 earnings at ($3.71) EPS, Q1 2025 earnings at ($2.39) EPS, Q2 2025 earnings at ($2.40) EPS, Q3 2025 earnings at $0.83 EPS, Q4 2025 earnings at $0.80 EPS and FY2025 earnings at ($3.15) EPS.

Several other equities research analysts have also recently weighed in on the stock. HSBC upgraded shares of BioNTech from a hold rating to a buy rating in a research note on Friday, August 2nd. Evercore ISI assumed coverage on shares of BioNTech in a research note on Tuesday, May 14th. They set an inline rating and a $100.00 price target for the company. BMO Capital Markets cut their price target on shares of BioNTech from $123.00 to $122.00 and set an outperform rating for the company in a research note on Tuesday, May 7th. JPMorgan Chase & Co. cut their price target on shares of BioNTech from $94.00 to $91.00 and set an underweight rating for the company in a research note on Thursday, August 15th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a hold rating to a buy rating and set a $95.00 price target for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, BioNTech currently has an average rating of Moderate Buy and a consensus target price of $109.09.

BioNTech Trading Up 0.7 %

Shares of NASDAQ:BNTX opened at $88.22 on Tuesday. The company has a market cap of $20.97 billion, a P/E ratio of 176.44 and a beta of 0.23. The stock’s 50-day moving average is $84.02 and its 200-day moving average is $89.34. BioNTech has a 52-week low of $76.53 and a 52-week high of $125.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the previous year, the business posted ($0.86) EPS. The firm’s quarterly revenue was down 23.3% on a year-over-year basis. Equities research analysts predict that BioNTech will post -2.04 earnings per share for the current year.

Institutional Trading of BioNTech

Several hedge funds have recently modified their holdings of BNTX. CWM LLC increased its holdings in shares of BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares in the last quarter. Frazier Financial Advisors LLC acquired a new stake in shares of BioNTech in the fourth quarter valued at approximately $30,000. First Horizon Advisors Inc. acquired a new stake in shares of BioNTech in the fourth quarter valued at approximately $38,000. Finally, Covestor Ltd increased its holdings in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.